Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer

被引:7
作者
Lindemann, Kristina [1 ,2 ]
Smogeli, Elisabeth [2 ]
Smastuen, Milada Cvancarova [3 ]
Bruheim, Kjersti [4 ]
Trovik, Jone [5 ,6 ]
Nordberg, Terje [7 ]
Kristensen, Gunnar B. [8 ]
Werner, Henrica M. J. [9 ]
Nakken, Esten [4 ]
机构
[1] Oslo Univ Hosp, Div Canc Med, Dept Gynecol Oncol, PB 4953 Nydalen, N-0424 Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Fac Med, POB 1171 Blindern, N-0318 Oslo, Norway
[3] Oslo Metropolitan Univ, Dept Nursing & Hlth Promot, Fac Hlth Sci, N-0166 Oslo, Norway
[4] Oslo Univ Hosp, Div Canc Med, Dept Oncol, PB 4953 Nydalen, N-0424 Oslo, Norway
[5] Univ Bergen, Dept Clin Sci, Ctr Canc Biomarkers, N-5020 Bergen, Norway
[6] Haukeland Hosp, Dept Obstet & Gynecol, N-5053 Bergen, Norway
[7] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway
[8] Oslo Univ Hosp, Div Canc Med, Dept Oncol, Inst Canc Genet & Informat, N-0424 Oslo, Norway
[9] Maastricht Univ, Med Ctr, Grow Sch Oncol & Dev Biol, Dept Obstet & Gynecol, POB 5800, NL-6202 AZ Maastricht, Netherlands
关键词
endometrial cancer; pelvic relapse; vaginal relapse; outcome; salvage radiation; EXTERNAL-BEAM RADIOTHERAPY; ISOLATED VAGINAL RECURRENCES; DOSE-RATE BRACHYTHERAPY; QUALITY-OF-LIFE; POSTOPERATIVE RADIOTHERAPY; OPEN-LABEL; CARCINOMA; SURGERY; MULTICENTER; PORTEC-2;
D O I
10.3390/cancers13061367
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary This multicenter retrospective study aimed to describe the outcomes of patients with endometrial cancer after central pelvic/vaginal relapse treated with radical radiotherapy (RT). We included 139 patients with a median follow-up time of 6.66 years. Patients were treated with external beam radiotherapy to elective pelvic lymph-node regions and boost to the pelvic tumor. During follow-up, 55 (39.6%) patients developed a second relapse, the majority (75%) with disease sites outside the radiation field. Risk group at primary diagnosis and type of boost administration were independent predictors of progression-free and overall survival. Five-year overall survival for the whole cohort was 68% (95% CI: 59-75%). The majority of isolated pelvic recurrences in RT-naive women with EC can be successfully salvaged by RT but survival in high-risk patients remains suboptimal. Individualizing of adjuvant treatment in first line and better treatment alternatives at relapse are important to ultimately improve survival. (1) Background: This study evaluated the clinical outcome after salvage radiotherapy for first pelvic relapse after endometrial cancer (EC). (2) Methods: This multicenter retrospective study included EC patients with first central pelvic relapse without lymph node involvement treated with curative intent. Progression-free (PFS) and overall survival (OS) were calculated with the Kaplan-Meier method and possible predictive factors for risk of relapse and mortality were identified using the Cox model. (3) Results: We included 139 patients with median EQD2 (Equivalent Dose in 2 Gy fractions) to the clinical target volume of 70.0 Gy. During follow up of median 6.66 years, 39.6% patients developed a second relapse. Risk group classification at primary diagnosis based on histology, grading and FIGO stage and how the pelvic tumor boost was administered were independently associated with PFS and OS. Five-year OS was 68% (95% CI (59-75)) for the whole cohort. Five-year OS was 88% (95% CI (75-94)), 72% (95% CI (55-84)) and 38% (95% CI (15-60)) for the stage I low-, intermediate- and high-risk group, respectively. (4) Conclusions: The majority of central pelvic recurrences in RT-naive EC women can be successfully salvaged with radiotherapy. However, survival in patients with high-risk disease remains poor and warrants a more individualized approach to optimize outcome.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 32 条
[1]  
AALDERS J, 1980, OBSTET GYNECOL, V56, P419
[2]   Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer [J].
Baek, Sungjae ;
Isohashi, Fumiaki ;
Yamaguchi, Hiroko ;
Mabuchi, Seiji ;
Yoshida, Ken ;
Kotsuma, Tadayuki ;
Yamazaki, Hideya ;
Tanaka, Eiichi ;
Sumida, Iori ;
Tamari, Keisuke ;
Otani, Keisuke ;
Seo, Yuji ;
Suzuki, Osamu ;
Yoshioka, Yasuo ;
Kimura, Tadashi ;
Ogawa, Kazuhiko .
BRACHYTHERAPY, 2016, 15 (06) :812-816
[3]   Survival of Danish Patients With Endometrial Cancer in the Intermediate-Risk Group Not Given Postoperative Radiotherapy The Danish Endometrial Cancer Study (DEMCA) [J].
Bertelsen, Kamma ;
Ortoft, Gitte ;
Hansen, Estrid Staehr .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (07) :1191-1199
[4]   Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results,, systematic review, and meta-analysis [J].
Blake, P. ;
Swart, Ann Marie ;
Orton, J. ;
Kitchener, H. ;
Whelan, T. ;
Lukka, H. ;
Eisenhauer, E. ;
Bacon, M. ;
Tu, D. ;
Parmar, M. K. B. ;
Amos, C. ;
Murray, C. ;
Qian, W. .
LANCET, 2009, 373 (9658) :137-146
[5]   Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy [J].
Chapman, Christopher H. ;
Maghsoudi, Kaveh ;
Littell, Ramey D. ;
Chen, Lee-May ;
Hsul, I. -Chow .
BRACHYTHERAPY, 2017, 16 (06) :1152-1158
[6]   ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up [J].
Colombo, N. ;
Creutzberg, C. ;
Amant, F. ;
Bosse, T. ;
Gonzalez-Martin, A. ;
Ledermann, J. ;
Marth, C. ;
Nout, R. ;
Querleu, D. ;
Mirza, M. R. ;
Sessa, C. .
ANNALS OF ONCOLOGY, 2016, 27 (01) :16-41
[7]   ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma [J].
Concin, Nicole ;
Matias-Guiu, Xavier ;
Vergote, Ignace ;
Cibula, David ;
Mirza, Mansoor Raza ;
Marnitz, Simone ;
Ledermann, Jonathan ;
Bosse, Tjalling ;
Chargari, Cyrus ;
Fagotti, Anna ;
Fotopoulou, Christina ;
Gonzalez Martin, Antonio ;
Lax, Sigurd ;
Lorusso, Domenica ;
Marth, Christian ;
Morice, Philippe ;
Nout, Remi A. ;
O'Donnell, Dearbhaile ;
Querleu, Denis ;
Raspollini, Maria Rosaria ;
Sehouli, Jalid ;
Sturdza, Alina ;
Taylor, Alexandra ;
Westermann, Anneke ;
Wimberger, Pauline ;
Colombo, Nicoletta ;
Planchamp, Francois ;
Creutzberg, Carien L. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) :12-39
[8]   Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma:: multicentre randomised trial [J].
Creutzberg, CL ;
van Putten, WLJ ;
Koper, PCM ;
Lybeert, MLM ;
Jobsen, JJ ;
Wárlám-Rodenhuis, CC ;
De Winter, KAJ ;
Lutgens, LCHW ;
van den Bergh, ACM ;
van de Steen-Banasik, E ;
Beerman, H ;
van Lent, M .
LANCET, 2000, 355 (9213) :1404-1411
[9]   Survival after relapse in patients with endometrial cancer:: results from a randomized trial [J].
Creutzberg, CL ;
van Putten, WLJ ;
Koper, PC ;
Lybeert, MLM ;
Jobsen, JJ ;
Wárlám-Rodenhuis, CC ;
De Winter, KAJ ;
Lutgens, LCHW ;
van den Bergh, ACM ;
van der Steen-Banasik, E ;
Beerman, H ;
van Lent, M .
GYNECOLOGIC ONCOLOGY, 2003, 89 (02) :201-209
[10]   Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial [J].
de Boer, Stephanie M. ;
Powell, Melanie E. ;
Mileshkin, Linda ;
Katsaros, Dionyssios ;
Bessette, Paul ;
Haie-Meder, Christine ;
Ottevanger, Petronella B. ;
Ledermann, Jonathan A. ;
Khaw, Pearly ;
D'Amico, Romerai ;
Fyles, Anthony ;
Baron, Marie-Helene ;
Jurgenliemk-Schulz, Ina M. ;
Kitchener, Henry C. ;
Nijman, Hans W. ;
Wilson, Godfrey ;
Brooks, Susan ;
Gribaudo, Sergio ;
Provencher, Diane ;
Hanzen, Chantal ;
Kruitwagen, Roy F. ;
Smit, Vincent T. H. B. M. ;
Singh, Naveena ;
Do, Viet ;
Lissoni, Andrea ;
Nout, Remi A. ;
Feeney, Amanda ;
Verhoeven-Adema, Karen W. ;
Putter, Hein ;
Creutzberg, Carien L. .
LANCET ONCOLOGY, 2019, 20 (09) :1273-1285